9,700 reports of this reaction
3.4% of all NATALIZUMAB reports
#4 most reported adverse reaction
MULTIPLE SCLEROSIS is the #4 most commonly reported adverse reaction for NATALIZUMAB, manufactured by Biogen Inc.. There are 9,700 FDA adverse event reports linking NATALIZUMAB to MULTIPLE SCLEROSIS. This represents approximately 3.4% of all 289,050 adverse event reports for this drug.
NATALIZUMAB has an overall safety score of 75 out of 100. Patients taking NATALIZUMAB who experience multiple sclerosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS is moderately reported among NATALIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to multiple sclerosis, the following adverse reactions have been reported for NATALIZUMAB:
The following drugs have also been linked to multiple sclerosis in FDA adverse event reports:
MULTIPLE SCLEROSIS has been reported as an adverse event in 9,700 FDA reports for NATALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS accounts for approximately 3.4% of all adverse event reports for NATALIZUMAB, making it a notable side effect.
If you experience multiple sclerosis while taking NATALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.